164 related articles for article (PubMed ID: 36292918)
1. CD44V3, an Alternatively Spliced Form of CD44, Promotes Pancreatic Cancer Progression.
Zhu H; Zhou W; Wan Y; Lu J; Ge K; Jia C
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36292918
[TBL] [Abstract][Full Text] [Related]
2. CD44 splice variant (CD44v3) promotes progression of urothelial carcinoma of bladder through Akt/ERK/STAT3 pathways: novel therapeutic approach.
Anand V; Khandelwal M; Appunni S; Gupta N; Seth A; Singh P; Mathur S; Sharma A
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2649-2661. PubMed ID: 31529191
[TBL] [Abstract][Full Text] [Related]
3. Frequent expression of the high molecular, 673-bp CD44v3,v8-10 variant in colorectal adenomas and carcinomas.
Kopp R; Fichter M; Schalhorn G; Danescu J; Classen S
Int J Mol Med; 2009 Nov; 24(5):677-83. PubMed ID: 19787202
[TBL] [Abstract][Full Text] [Related]
4. Down regulation of U2AF1 promotes ARV7 splicing and prostate cancer progression.
Cao H; Wang D; Gao R; Chen L; Feng Y
Biochem Biophys Res Commun; 2021 Feb; 541():56-62. PubMed ID: 33477033
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth.
Bourguignon LY; Zhu H; Zhou B; Diedrich F; Singleton PA; Hung MC
J Biol Chem; 2001 Dec; 276(52):48679-92. PubMed ID: 11606575
[TBL] [Abstract][Full Text] [Related]
6. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers.
Olsson E; Honeth G; Bendahl PO; Saal LH; Gruvberger-Saal S; Ringnér M; Vallon-Christersson J; Jönsson G; Holm K; Lövgren K; Fernö M; Grabau D; Borg A; Hegardt C
BMC Cancer; 2011 Sep; 11():418. PubMed ID: 21957977
[TBL] [Abstract][Full Text] [Related]
7. Characterization of CD44v3-containing isoforms in head and neck cancer.
Reategui EP; de Mayolo AA; Das PM; Astor FC; Singal R; Hamilton KL; Goodwin WJ; Carraway KL; Franzmann EJ
Cancer Biol Ther; 2006 Sep; 5(9):1163-8. PubMed ID: 16855392
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
Bourguignon LY; Wong G; Earle C; Chen L
J Biol Chem; 2012 Sep; 287(39):32800-24. PubMed ID: 22847005
[TBL] [Abstract][Full Text] [Related]
9. Direct interaction of TrkA/CD44v3 is essential for NGF-promoted aggressiveness of breast cancer cells.
Trouvilliez S; Cicero J; Lévêque R; Aubert L; Corbet C; Van Outryve A; Streule K; Angrand PO; Völkel P; Magnez R; Brysbaert G; Mysiorek C; Gosselet F; Bourette R; Adriaenssens E; Thuru X; Lagadec C; de Ruyck J; Orian-Rousseau V; Le Bourhis X; Toillon RA
J Exp Clin Cancer Res; 2022 Mar; 41(1):110. PubMed ID: 35346305
[TBL] [Abstract][Full Text] [Related]
10. Expression of CD44 in pancreatic cancer and its significance.
Li XP; Zhang XW; Zheng LZ; Guo WJ
Int J Clin Exp Pathol; 2015; 8(6):6724-31. PubMed ID: 26261555
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R
Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306
[TBL] [Abstract][Full Text] [Related]
12. Chitinase 3-like 1-CD44 interaction promotes metastasis and epithelial-to-mesenchymal transition through β-catenin/Erk/Akt signaling in gastric cancer.
Geng B; Pan J; Zhao T; Ji J; Zhang C; Che Y; Yang J; Shi H; Li J; Zhou H; Mu X; Xu C; Wang C; Xu Y; Liu Z; Wen H; You Q
J Exp Clin Cancer Res; 2018 Aug; 37(1):208. PubMed ID: 30165890
[TBL] [Abstract][Full Text] [Related]
13. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met.
van der Voort R; Taher TE; Wielenga VJ; Spaargaren M; Prevo R; Smit L; David G; Hartmann G; Gherardi E; Pals ST
J Biol Chem; 1999 Mar; 274(10):6499-506. PubMed ID: 10037743
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of CD44 standard, variant isoforms 3 and 6 and -catenin expression in local prostate cancer treated by radical prostatectomy.
Aaltomaa S; Lipponen P; Viitanen J; Kankkunen JP; Ala-Opas M; Kosma VM
Eur Urol; 2000 Nov; 38(5):555-62. PubMed ID: 11096236
[TBL] [Abstract][Full Text] [Related]
15. TGF-β1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44.
Chen Q; Gu M; Cai ZK; Zhao H; Sun SC; Liu C; Zhan M; Chen YB; Wang Z
Cell Mol Life Sci; 2021 Feb; 78(3):949-962. PubMed ID: 32440711
[TBL] [Abstract][Full Text] [Related]
16. EMP1 regulates cell proliferation, migration, and stemness in gliomas through PI3K-AKT signaling and CD44.
Wang J; Li X; Wu H; Wang H; Yao L; Deng Z; Zhou Y
J Cell Biochem; 2019 Oct; 120(10):17142-17150. PubMed ID: 31111534
[TBL] [Abstract][Full Text] [Related]
17. A Novel Anti-CD44 Variant 3 Monoclonal Antibody C
Suzuki H; Kitamura K; Goto N; Ishikawa K; Ouchida T; Tanaka T; Kaneko MK; Kato Y
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176118
[TBL] [Abstract][Full Text] [Related]
18. The CD44 standard isoform contributes to radioresistance of pancreatic cancer cells.
Tsubouchi K; Minami K; Hayashi N; Yokoyama Y; Mori S; Yamamoto H; Koizumi M
J Radiat Res; 2017 Nov; 58(6):816-826. PubMed ID: 29106581
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of CD44 inhibits proliferation, migration and invasion of osteosarcoma cells accompanied by downregulation of cathepsin S.
Kong L; Ji H; Gan X; Cao S; Li Z; Jin Y
J Orthop Surg Res; 2022 Mar; 17(1):154. PubMed ID: 35264209
[TBL] [Abstract][Full Text] [Related]
20. Colocalization of basic fibroblast growth factor and CD44 isoforms containing the variably spliced exon v3 (CD44v3) in normal skin and in epidermal skin cancers.
Grimme HU; Termeer CC; Bennett KL; Weiss JM; Schöpf E; Aruffo A; Simon JC
Br J Dermatol; 1999 Nov; 141(5):824-32. PubMed ID: 10583162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
